Out

West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak

WNVis a positive single-stranded RNA flavivirus of about 11 kb. It primarily infe...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

PHILADELPHIA, July 3, 2007-- – The appearance of arash in cancer patients treated with erlotinib (Tarceva) isstrongly associated with longer survival, according to researchersfrom the drug’s developer, OSI Pharmaceuticals, Inc. This isnot the first time that rash has been associated with a survivaladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib...

Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo

ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced CellTechnology, Inc. (OTCBB: ACTC) has successfully produced a humanembryonic stem cell (hESC) line without destroying an embryo at itslab in Worcester, Massachusetts. This development was announced byRobert Lanza, M.D., V.P. of Research and Scientific Development ofAdvanced Cell Technology (ACT) on Tuesday at the fifth annualmeeting...

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

Data from the PROactive and CHICAGO studies of ACTOS(R)(pioglitazone HCl) will be presented in poster format at the 67thScientific Sessions of the American Diabetes Association inChicago: -- Hospitalizations for serious adverse events in high-risk type 2 diabetes patients treated with pioglitazone for 3...

Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits

NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase ActivationSciences, Inc. (T.A. Sciences) recently announced the results ofthe Pivotal 2005 Anti-Aging Trial of TA-65, the first human trialever to show demonstrated, measurable and positive anti-agingbenefits from a Telomerase Activator. Statistically significantresults were found in those taking TA-65 across several keyconditions of agi...

Women Well-Informed About Breast Cancer, Yet Lacking Knowledge About Current Treatments, New Survey Finds

-- CancerCare offers five questions to help womenlearn about breast cancer therapy advances -- NEW YORK, June 12, 2007 – According to a newGfK Roper Public Affairs survey sponsored by CancerCare, a nationalnonprofit cancer support organization, while the majority (76percent) of women surveyed said they know at least a fair amountabout breast cancer...

International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinson's Disease

Results presented at the Movement Disorder Society's 11thInternational Congress in Istanbul, Turkey KANSAS CITY, Mo., June 08, 2007 /PRNewswire-FirstCall/ -- Newinformation on the use of AZILECT(R) (rasagiline tablets) for thetreatment of Parkinson's disease (PD) was reported this week at TheMovement Disorder Society's congress in Istanbul, Turkey.Once-daily AZILECT was approved by the FD...

Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 2007 - SavientPharmaceuticals, Inc. (NASDAQ: SVNT) announced today that twoabstracts exploring Phase 2 Puricase(R) (PEG-uricase) data andquality of life in treatment-failure gout patients will bepresented at the European League Against Rheumatism (EULAR) 2007Annual Congress taking place June 13 - 16th in Barcelona, Spain.Puricase is a PEGylated...

New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents and Small Vessel Size To BeIndependent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX NewsNetwork/ -- An analysis of data from the Western Denmark HeartRegistry found that patients who received the CYPHER(R)Sirolimus-eluting Coronary...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the TAXUS(R)...

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- A three-yearfollow-up subset analysis presented today as a late-breakingclinical trial at EuroPCR 2007 showed that the CYPHER(R)Sirolimus-eluting Coronary Stent had results comparable to coronaryartery bypass grafting (CABG or bypass surgery) and better outcomesthan bare metal stents (BMS) in diabetic patients with blockages intw...

New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder

- Data Presented at 2007 APA Meeting - COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Datafrom four new studies examining safety and efficacy ofdesvenlafaxine succinate, a serotonin-norepinephrine reuptakeinhibitor (SNRI) being studied as a potential treatment for adultswith major depressive disorder (MDD), were presented today at the2007 American Psychiatric Association annual...

FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications

ROCKVILLE, Md., May 2, 2007-The U.S. Food and DrugAdministration (FDA) today proposed that makers of allantidepressant medications update the existing black box warning ontheir products' labeling to include warnings about increased risksof suicidal thinking and behavior, known as suicidality, in youngadults ages 18 to 24 during initial treatment (generally the firstone to two months).</p...

Ad hoc: Interim report about clinical trial of BF-200 ALA in actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announcedthat an interim report regarding the clinical study of BF-200 ALAin actinic keratosis was received today from an independent reviewcommittee. The objectives of the study are to investigate theefficacy and safety of several doses of BF-200 ALA in photodynamictherapy. The comments received today refer to the clinical resultseight...

Doctors Outraged Over Growth Hormone Controversy

Two anti-aging preventative medicine doctors say they are outragedover recent media coverage about their advocacy of prescribinghuman growth hormone to treat a hormone deficiency often associatedwith aging. DAYTONA BEACH, Fla., April 27, 2007 /PRNewswire/ -- The adultuse of human growth hormone (HGH) was at the center of a recent NewYork Times article about the founders of the American Ac...

Cortex Area Thinner in Youth with Alzheimers-Related Gene

BETHESDA, Md., April 23, 2007--A part of the brain firstaffected by Alzheimers disease (<a target="_blank" href="http://www.nia.nih.gov/Alzheimers/">http://www.nia.nih.gov/Alzheimers/ )is thinner in youth with a risk gene for the disorder, a brainimaging study by researchers at the National Institute of MentalHealth (NIMH), one of the National Institutes of Health (NIH), hasfound. A t...

Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment

DALLAS, Texas and NUTLEY, N.J., April 23, 2007 /PRNewswire/ --An activity-based cost analysis demonstrated that if a renal anemiatreatment administered once every four weeks replaced thrice weeklyadministration of epoetin alfa, hemodialysis centers may save anestimated 802 nursing hours and more than $44,000 per year per 100patients. These data, from a multi-center prospective analysis of...

Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

GENEVA, April 17, 2007 /PRNewswire/ -- Addex Pharmaceuticalsannounced today the successful completion of a Phase IIa proof ofconcept trial with its lead compound ADX10059 in patients withgastro-esophageal reflux disease (GERD), a highly prevalentcondition with a significant unmet medical need. The study achievedits primary objective, the control of 24-hour esophageal pH, withstatistical...

Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease

ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007/PRNewswire-FirstCall/ -- Data analyses from the largest initialregistration clinical trial program ever undertaken in the renalanemia arena provide efficacy and safety information on theinvestigational anemia therapy MIRCERA(TM) for the treatment ofrenal anemia associated with chronic kidney disease (CKD) inpatients on dialysis and not on di...

Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting

BIRMINGHAM, Ala., April 03, 2007 /PRNewswire/ -- SouthernResearch Institute, a not-for-profit organization that conductsbasic and applied research in the areas of preclinical drugdiscovery and drug development today announced that its scientistswill be delivering one oral presentation and 10 posterpresentations at the 2007 American Association for Cancer Research(AACR) Annual Meeting, Ap...

Six Important Things to Know About Preventing Hospital Infections

Infection Control Professional Offers Patient Tips to Guard AgainstHospital Infections KANSAS CITY, Kan., April 02, 2007 /PRNewswire/ -- Hospitalinfections are among the top ten leading causes of death in theUnited States, according to the Centers for Disease Control. Thereare countless stories about patients who go into hospitals withminor conditions and leave under much graver circumsta...

Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation

Novel Approach to Address Growing Problem of Antibiotic ResistancePublished in Nature Biotechnology VANCOUVER, British Columbia, March 26, 2007 /PRNewswire/ --Inimex Pharmaceuticals Inc.'s product candidate IDR-1 is the firstimmune system trigger to cure infections without causing harmfulinflammation, according to a paper published in the April 2007issue of Nature Biotechnology. Th...

The American Liver Foundation Urges Cautious Optimism about CDC Report on Declining Acute Hepatitis Infection Rates

Focus Must Remain on the Millions Still Suffering from ChronicHepatitis B and C NEW YORK, March 21, 2007 /PRNewswire/ -- The Centers for DiseaseControl and Prevention (CDC) has reported that significant declinein the rates of new acute hepatitis infections in the United Statesin the last 10 years, reflecting the success of hepatitis A and Bvaccination programs. The American Liver Foundati...

Researchers Find Surprising Pattern of Influenza Spread in South America and Tropics

BETHESDA, Md., March 20, 2007--Researchers studying influenzatransmission patterns in the Southern Hemisphere and in tropicalareas, specifically Brazil, uncovered the unexpected finding thateach season influenza travels from low populated regions near theequator to the more populated centers. Their work, funded by theFogarty International Center (NIH), part of the National Institutesof H...

REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis

- The Reduction of Atherothrombosis for Continued Health(REACH) PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-yearresults paper published today in the Journal of the AmericanMedical Association (JAMA) show that outpatients withatherothrombosis have a surprisingly high risk of death or majorcardiovascular illness, especially if more than...

Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results

RICHMOND, British Columbia, March 12, 2007--InflazymePharmaceuticals Ltd. (TSX: IZP). As announced on January 29, 2007,the preliminary results of the Phase 2b CAPSICS study withIPL512,602 showed no statistical or clinical difference betweenpatients who received drug or placebo. However, the placeboresponse was surprisingly large and consistent across a number ofthe end-points, which prom...

POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc.(NASDAQ: POZN), today announced top-line results of its "SaferAspirin" PA 325 proof-of-concept study conducted during the fourthquarter of 2006. PA 325 is a patented formulation of 325mg ofaspirin surrounded by a 20mg coating of an immediate releaseformulation of a proton pump inhibitor. The PA 325, 28 day study, involved two gro...

Pozen Announces Positive Outcome for PA 325

Chapel Hill, N.C., March 6, 2007-Pozen Inc. (NASDAQ: POZN),today announced top-line results of its "Safer Aspirin" PA 325proof-of-concept study conducted during the fourth quarter of 2006.PA 325 is a patented formulation of 325mg of aspirin surrounded bya 20mg coating of an immediate release formulation of a proton pumpinhibitor. The PA 325, 28 day study, involved two groups of 40...